CytoDyn Announces New CEO Dr. Jacob Lalezari and Interim CFO Mitchell Cohen

VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Biotechnology firm CytoDyn Inc. CYDY, known for its development of the CCR5 antagonist leronlimab, has undergone significant leadership changes. The company has officially appointed Dr. Jacob Lalezari as its new Chief Executive Officer. A seasoned veteran in the field of clinical research, Dr. Lalezari brings a wealth of experience to CytoDyn, specifically in the realm of HIV treatment and research. His expertise is anticipated to drive the company's pipeline product, leronlimab, forward in its multiple therapeutic applications, including HIV, cancer, and immune-mediated illnesses.

Leadership with a Vision

Dr. Lalezari's appointment as CEO marks a milestone in CytoDyn's quest to establish leronlimab as a breakthrough treatment option. His prior experience in clinical trials and research in innovative treatments will be a cornerstone for CytoDyn's strategic direction. The company also introduced Mitchell Cohen as the Interim Chief Financial Officer. Cohen’s financial acumen will guide CytoDyn through its next phase of growth and operational efficiency, ensuring the financial stability and planning necessary for the company's ongoing clinical trials and potential commercial launches.

Impact on CytoDyn's Future

The leadership changes come at a pivotal time for CytoDyn as it navigates the regulatory pathway for leronlimab. With Dr. Lalezari at the helm, the company is expected to leverage his extensive network and deep understanding of FDA regulatory processes to accelerate leronlimab’s progress. Meanwhile, Mitchell Cohen is set to shore up the company's financial foundation, aligning the fiscal strategy with the organizational objectives that Dr. Lalezari envisions. CytoDyn's shareholders are likely to watch closely as these appointments unfold in shaping the company's trajectory.

CytoDyn, CEO, CFO, leronlimab, CCR5